Go Pro
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$261.23
+0.2%		$257.64
$186.05
▼
$282.15
$16.27B0.35528,187 shs504,938 shs
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$65.51
+1.7%		$63.16
$49.26
▼
$70.98
$12.47B0.241.72 million shs2.20 million shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
+0.16%-3.65%+2.62%+19.80%+31.63%
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
+1.71%-1.38%-5.81%+17.09%+20.20%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$261.23
+0.2%		$257.64
$186.05
▼
$282.15
$16.27B0.35528,187 shs504,938 shs
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$65.51
+1.7%		$63.16
$49.26
▼
$70.98
$12.47B0.241.72 million shs2.20 million shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
+0.16%-3.65%+2.62%+19.80%+31.63%
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
+1.71%-1.38%-5.81%+17.09%+20.20%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.05
Buy$310.0018.67% Upside
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
2.74
Moderate Buy$89.1736.12% Upside

Current Analyst Ratings Breakdown

Latest ASND and BMRN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/10/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$344.00
9/10/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/10/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
9/10/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$60.00
9/3/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D) ➝ Sell (D+)
9/1/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$304.00 ➝ $312.00
9/1/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$275.00 ➝ $273.00
9/1/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$327.00
9/1/2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$88.00 ➝ $90.00
8/31/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$333.00 ➝ $330.00
8/31/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Stifel Nicolaus logo
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$328.00 ➝ $326.00
(Data available from 9/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$814.57M20.01N/AN/A($2.97) per share-87.96
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$3.22B3.94$2.90 per share22.58$31.68 per share2.07
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$258M$12.8920.2729.35N/A70.99%32.54%7.71%11/11/2026 (Estimated)
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$348.90M$0.37177.0512.020.462.14%5.32%3.69%10/26/2026 (Estimated)

Latest ASND and BMRN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$1.71$1.0270-$0.6830$3.23$376.75 million$387.22 million
8/6/2026Q2 2026
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
$0.95$1.20+$0.25$0.23$932.03 million$989.71 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.27
2.99
2.32
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
0.56
2.39
1.32

Institutional Ownership

CompanyInstitutional Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
98.71%

Insider Ownership

CompanyInsider Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
40.00%
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
0.68%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
1,18962.38 million37.43 millionOptionable
BioMarin Pharmaceutical Inc. stock logo
BMRN
BioMarin Pharmaceutical
3,221193.57 million192.26 millionOptionable

Recent News About These Companies

BioMarin Pharmaceutical Inc. $BMRN Shares Sold by Engineers Gate Manager LP
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-biomarin-pharmaceutical-inc-bmrn-shares-sold-by-engineers-gate-manager-lp-2026-09-11/
BioMarin Pharmaceutical Inc. (BMRN) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
September 10 at 6:00 PM  |  seekingalpha.comhttps://seekingalpha.com/article/4945200-biomarin-pharmaceutical-inc-bmrn-presents-at-citigroups-biopharma-back-to-school-summit-2026
BioMarin Pharmaceutical Inc. (BMRN) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
September 10 at 2:00 PM  |  seekingalpha.comhttps://seekingalpha.com/article/4945116-biomarin-pharmaceutical-inc-bmrn-presents-at-12th-annual-cantor-fitzgerald-global-healthcare
BioMarin Pharmaceutical (NASDAQ:BMRN) Receives "Neutral" Rating from HC Wainwright
September 10 at 8:05 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-biomarin-pharmaceutical-nasdaq-bmrn-receives-neutral-rating-from-hc-wainwright-2026-09-10/
BioMarin Pharmaceutical Inc. (BMRN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
September 9 at 8:00 PM  |  seekingalpha.comhttps://seekingalpha.com/article/4944741-biomarin-pharmaceutical-inc-bmrn-presents-at-wells-fargo-21st-annual-healthcare-conference
BioMarin Pharmaceutical Inc.: BioMarin Announces Positive Results of Phase 3 VOXZOGO (vosoritide) Study in Hypochondroplasia Published in NEJM Evidence
September 9 at 6:12 PM  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-09/69535575-biomarin-pharmaceutical-inc-biomarin-announces-positive-results-of-phase-3-voxzogo-vosoritide-study-in-hypochondroplasia-published-in-nejm-evidenc-008.htm
BioMarin Reports Positive Phase 3 Results For VOXZOGO
September 9 at 1:11 PM  |  rttnews.comhttps://www.rttnews.com/3689627/biomarin-reports-positive-phase-3-results-for-voxzogo.aspx
BioMarin's VOXZOGO Hits Phase 3 Growth Endpoint In Hypochondroplasia
September 9 at 1:11 PM  |  rttnews.comhttps://www.rttnews.com/3689668/biomarin-s-voxzogo-hits-phase-3-growth-endpoint-in-hypochondroplasia.aspx
BioMarin Announces Positive Results of Phase 3 VOXZOGO® (vosoritide) Study in Hypochondroplasia Published in NEJM Evidence
September 9 at 9:05 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/biomarin-announces-positive-results-of-phase-3-voxzogo-vosoritide-study-in-hypochondroplasia-published-in-nejm-evidence-302873026.html
VIRGINIA RETIREMENT SYSTEMS ET Al Buys New Stake in BioMarin Pharmaceutical Inc. $BMRN
September 9 at 5:12 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-virginia-retirement-systems-et-al-buys-new-stake-in-biomarin-pharmaceutical-inc-bmrn-2026-09-09/
BioMarin Pharmaceutical Inc. $BMRN Shares Acquired by Hsbc Holdings PLC
September 9 at 3:44 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-biomarin-pharmaceutical-inc-bmrn-shares-acquired-by-hsbc-holdings-plc-2026-09-09/
3 reasons to avoid BMRN and 1 stock to buy instead
September 8 at 10:09 PM  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/3-reasons-to-avoid-bmrn-and-1-stock-to-buy-instead/ar-AA2bNOAO
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Consensus Rating of "Moderate Buy" by Analysts
September 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31005942
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Average Recommendation of "Moderate Buy" by Analysts
September 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-biomarin-pharmaceutical-inc-nasdaq-bmrn-given-average-recommendation-of-moderate-buy-by-analysts-2026-09-06/
Public Employees Retirement System of Ohio Purchases Shares of 60,483 BioMarin Pharmaceutical Inc. $BMRN
September 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-public-employees-retirement-system-of-ohio-purchases-shares-of-60483-biomarin-pharmaceutical-inc-bmrn-2026-09-05/
How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset
September 3, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2984720/how-biomarin-turned-a-competitive-threat-into-a-royalty-bearing-asset?cid=cs-stocknewsapi-ft-analyst_blog|quick_take-2984720
Empowered Funds LLC Takes Position in BioMarin Pharmaceutical Inc. $BMRN
September 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-empowered-funds-llc-takes-position-in-biomarin-pharmaceutical-inc-bmrn-2026-09-03/
Piper Sandler Raises BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target to $90.00
September 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31000054
BioMarin to Participate in Upcoming Investor Conferences
September 2, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/biomarin-to-participate-in-upcoming-investor-conferences-302866797.html
BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Price Expected to Rise, Jefferies Financial Group Analyst Says
September 2, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30997712
HC Wainwright Forecasts Strong Price Appreciation for BioMarin Pharmaceutical (NASDAQ:BMRN) Stock
September 2, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30997704

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$261.23 +0.42 (+0.16%)
Closing price 09/10/2026 04:00 PM Eastern
Extended Trading
$259.90 -1.33 (-0.51%)
As of 04:11 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

BioMarin Pharmaceutical stock logo

BioMarin Pharmaceutical NASDAQ:BMRN

$65.51 +1.10 (+1.71%)
Closing price 09/10/2026 04:00 PM Eastern
Extended Trading
$66.14 +0.63 (+0.96%)
As of 06:06 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas